
Registration of generics in Russia
We combine 20 years of experience in Europe with the understanding of Russian needs. In addition to Czech and English, our team can also communicate in Russian, which, together with the comprehensive understanding of the European, US and Russian regulatory requirements in combination with our extensive experience, makes our services very competitive, especially in GxP, analysis, and bioavailability/bioequivalence).
Since 2010, Quinta has conducted or participated in more than 25 bioequivalence studies in Russia. We have a joint venture with the registered office in Russia, which owns clinical BA/BE facility with 44 beds and in addition to our Prague laboratory, we also have a joint bio-analytical laboratory in Russia. Our Russian joint venture operates according to our own European working procedures adapted to the current Russian legal regulations. We continuously inspect and improve the performance of our Russian partners. We also cooperate with Russian partner workplaces in pre‑clinical studies (required now by Russian law). We have a general understanding of the Russian regulatory strategy in area of generics.
Quinta offers comprehensive services to companies focusing on the Russian generic market. Whether you seek assistance with regulatory submissions in Russia, want to conduct pre-clinical generic studies or require complete clinical and bioanalytical services (bioavailability/bioequivalence (BA/BE)), our R&D, regulatory and medical team can provide you with all the support you need.
We offer the following services in Russia (all the services are available in English and Russian):
- Developmental hypothesis and evaluation of BA / BE milestones
- Type of study (for example 2 ways, fully replicated, two-stage, etc.) in accordance with the current Russian guidelines
- Calculation of the sample size, estimation of variability, optimization of blood sampling, studied population
- Selection of the clinical location for the BA/BE study in Russia
- Support for development (estimation of treatment differences using in vitro data)
- Own internal pharmacokinetics and statistical investigation (more than 350 data files, molecules). Cost-effective solutions (tenders and CRO qualifications), complete management of the BA/BE study
- Cost-effective solutions (CROs and CROs), complete management of the BA / BE study
- Import of drugs, export of plasma samples
- Approval by the Russian ethics commission
- Full clinical management, monitoring, quality Full clinical management, monitoring, quality assurance
- Bioanalytics and statistics
- Medical documentation also in Russian
- Compilation of the final report in Russian
- Quality assurance, GMP, GCP, GLP
In September 2010, the new Federal Law No. 61 "On Drug Circulation" came into effect in the Russian Federation. This law introduced a number of changes in the drug registration system. One of the most significant changes is the general requirement to conduct bioavailability/bioequivalence studies in Russia for all newly registered medicinal products for oral administration. This requirement has led to significant changes in the field of clinical trials in Russia: Since 2010, the requirement for the bioequivalence study to be conducted in Russia applies also to foreign companies regardless of whether they have already conducted these studies with the same medicinal product in other countries.
Even if the reference medicinal product is globally registered in the EU, US or other countries and its first bioequivalence study was conducted in the EU, Canada, USA, etc. with the same global original medicinal product as reference, the study should also be conducted in the Russian federation.